Cardiovascular diseases
2024 Activity indicators
- 2 competitive European projects led: RETENTION (H2020) y STRATIFY-HF (HE)
- 6 national public projects led: ISCIII, MICINN
- 9 private projects led
- 54 clinical trials led
- 95 publications
- IF: 808.37
- Q1 publications: 59 (62%)
- D1 publications: 37 (39%)
- 3 thesis
- 2 awards/recognitions
- Members of editorial committees: 5 researchers
- 1 international patent (EP11845312,5) "Possible use of EMMPRIN inhibitors for the treatment of cardiac damage after ischemia-reperfusion" (Authors: Dr. Carlos Zaragoza et al.) and another in application phase
Milestones
- First European Lump Sum financing project awarded "FH-EARLY 101155885: New strategies for the EARLY diagnosis, risk stratification and co-management of familial hypercholesterolemia".
- CIBER - SPANISH I study. Prospective, randomized, multicenter, open-label, event-driven study to evaluate the non-inferiority of a personalized precision strategy for the prevention of sudden death in patients with non-ischemic dilated cardiomyopathy. PI in our center: Dr. Marta Jiménez-Blanco.
- First European project of the ERASMUS program awarded. "XiA: Xpanding Innovative Alliance for interoperability skills in digital health".
- Dr. Cristina Lozano appointed President of the Young Cardiologists Group of the Spanish Society of Cardiology.
- Dr. Zamorano obtains various appointments and recognitions, including: Academician of the Royal National Academy of Medicine of Spain, Director of the European PCR TRICUSPID Focus Group, Co-Director of the Interventional Echocardiography Congress (Milan, 2024).
Bibliometrics
Articles | Accum. IF | Mean IF | Articles Q1 or Q2 | % in Q1 or Q2 | Articles D1 | % in D1 | |
---|---|---|---|---|---|---|---|
2020 | 87 | 372.38 | 4.28 | 48 | 55 | 14 | 16 |
2021 | 95 | 637.15 | 6.71 | 73 | 77 | 20 | 21 |
2022 | 102 | 999.40 | 9.80 | 74 | 73 | 30 | 29 |
2023 | 83 | 567.62 | 6.60 | 64 | 74 | 15 | 17 |
2024 | 95 | 808.37 | 8.51 | 69 | 73 | 37 | 39 |
465 | 3384.92 | 7.18 | 328 | 71 | 116 | 25 |
* Only original articles, editorials, guidelines and reviews